At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 9, 2026 at 06:35 ET
Abeona Therapeutics reported Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially, with a net loss of -$0.08 per share, beating the consensus EPS estimate of -$0.17. The company also announced a $30M PIPE financing and the acquisition of Phase 3-ready ABO-801 for EoE, which together dilute existing shareholders by approximately 13-15%.
- Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially from $11.4M in Q2 2026
- Net loss of $(4.8)M or $(0.08) per share, compared to consensus EPS estimate of $(0.17)
- Cash, cash equivalents and short-term investments of $134.9M as of September 30, 2026
- Separately announced $30M PIPE financing at $3.75 per share and acquisition of ABO-801 for $20M in stock
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access